Dimensional Fund Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Dimensional Fund Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.91M	Buy	511,461 +240,611	+89%	+$812K	﹤0.01%	2709
2025 Q4	$815K	Buy	270,850 +106,606	+65%	+$269K	﹤0.01%	2890
2025 Q3	$312K	Sell	164,244 -43,029	-21%	-$75K	﹤0.01%	3063
2025 Q2	$295K	Sell	207,273 -147,576	-42%	-$200K	﹤0.01%	3071
2025 Q1	$543K	Buy	354,849 +115,254	+48%	+$246K	﹤0.01%	2989
2024 Q4	$594K	Buy	239,595 +162,785	+212%	+$405K	﹤0.01%	3005
2024 Q3	$88.3K	Buy	76,810 +51	+0.1%	+$63	﹤0.01%	3250
2024 Q2	$84.4K	Sell	76,759 -12,302	-14%	-$14.5K	﹤0.01%	3269
2024 Q1	$110K	Sell	89,061 -98,492	-53%	-$117K	﹤0.01%	3248
2023 Q4	$197K	Sell	187,553 -74,180	-28%	-$226K	﹤0.01%	3201
2023 Q3	$1.79M	Buy	261,733 +161,276	+161%	+$1.38M	﹤0.01%	2808
2023 Q2	$1.04M	Sell	100,457 -37,466	-27%	-$339K	﹤0.01%	2922
2023 Q1	$1.12M	Buy	137,923 +89,906	+187%	+$1.14M	﹤0.01%	2877
2022 Q4	$756	Hold	48,017	–	–	﹤0.01%	2966
2022 Q3	$756K	Buy	+48,017	New	+$756K	﹤0.01%	2959
2021 Q4	–	Sell	-18,640	Closed	-$336K	–	3540
2021 Q3	$336K	Hold	18,640	–	–	﹤0.01%	3255
2021 Q2	$327K	Hold	18,640	–	–	﹤0.01%	3245
2021 Q1	$470K	Hold	18,640	–	–	﹤0.01%	3155
2020 Q4	$121K	Buy	18,640 +8	+0%	+$34	﹤0.01%	3265
2020 Q3	$48K	Buy	18,632 +7,219	+63%	+$16.2K	﹤0.01%	3307
2020 Q2	$18K	Hold	11,413	–	–	﹤0.01%	3334
2020 Q1	$12K	Hold	11,413	–	–	﹤0.01%	3367
2019 Q4	$22K	Sell	11,413 -533,312	-98%	-$884K	﹤0.01%	3369
2019 Q3	$588K	Sell	544,725 -356,318	-40%	-$505K	﹤0.01%	3117
2019 Q2	$1.97M	Buy	901,043 +151,916	+20%	+$828K	﹤0.01%	2904
2019 Q1	$4.49M	Buy	749,127 +259,611	+53%	+$1.72M	﹤0.01%	2683
2018 Q4	$3.62M	Buy	489,516 +250,963	+105%	+$2.59M	﹤0.01%	2700
2018 Q3	$3.46M	Buy	238,553 +222,836	+1,418%	+$3.82M	﹤0.01%	2782
2018 Q2	$314K	Hold	15,717	–	–	﹤0.01%	3190
2018 Q1	$275K	Hold	15,717	–	–	﹤0.01%	3187
2017 Q4	$388K	Buy	+15,717	New	+$383K	﹤0.01%	3130

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors's ACRS Position: Q1 2026 in Review

Dimensional Fund Advisors increased its Aclaris Therapeutics (ACRS) stake by 89% in Q1 2026, buying an estimated $812K and bringing the position to 511,461 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #2709.

Dimensional Fund Advisors first reported a position in ACRS in Q4 2017 and has held it in 31 quarters since. The position peaked at $4.49M in Q1 2019. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

Dimensional Fund Advisors held 511,461 shares of Aclaris Therapeutics worth $1.91M as of Q1 2026.
Dimensional Fund Advisors bought 240,611 Aclaris Therapeutics shares in Q1 2026, an estimated $812K.
Aclaris Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2709 holding.
Dimensional Fund Advisors first reported a position in Aclaris Therapeutics in Q4 2017 and has held it in 31 quarters since.
Dimensional Fund Advisors's Aclaris Therapeutics position peaked at $4.49M in Q1 2019.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.